Targeted Therapeutics Research Award
National Lung Cancer Partnership/LUNGevity Foundation Research Grant
Mark W. Onaitis, MD
Duke University
Durham
NC
The KRAS gene is the most common mutation in non-small cell lung cancer. Dr. Onaitis is studying how mutations of the KRAS gene affect different types of cells in the lungs and how these differences can be used to develop a targeted therapy that can lessen the effects of KRAS in lung cancer cells.